NEWS

To be able to provide accurate result and to perform reliable experiments our facilities are at the top of the line and our equipment of high quality. We spare no expense to make sure these goals are met and just recently we received a donation which made us able to refresh our labs with new laboratory equipment. We used ScienceInTheTriangle (see link below), a newly started company that provides laboratory equipment of a wide variety. They have agreed to partner up with us and gave us great deal on a number of new laboratory gear and machines.

The deal concerned a new spectrophotometer, new laboratory scales and colorimeters, but first and foremost a whole new set of refractometers. Refractometers are used on a daily basis in our labs and we rely on them to get accurate data. We got samples of their equipment for evaluation and after having used it for about two weeks our scientists are more than happy with their performance.

We are always careful to meet the high standards required in order to achieve reliable and repeatable results and will seek new and better solutions for problems and obstacles, why we are always looking for new partners and possible employments. Don’t hesitate to contact us if you feel you have something new for us!

Ceregene’s unique combination of proprietary position, research, product development, and clinical expertise will allow it to develop its growth factor treatments into a commercial reality for treating neurodegenerative disorders.

Ceregene, Inc. is a private, San Diego-based biotechnology company focused on developing neurotrophic growth factor treatments for major neurodegenerative disorders using a proprietary gene delivery technology. Founded in 2001, Ceregene raised $10.5M in initial financing and another $32M in 2004. The company has a highly motivated and efficient team of about 30 employees led by a seasoned management team, Board of Directors, and Scientific Advisory Board.

In its short history, Ceregene has already brought gene therapy products for Alzheimer’s disease and Parkinson’s disease through pre-clinical development and into clinical trials. Ceregene also has research programs investigating therapies for other neurodegenerative disorders for which no effective treatment exists, such as amyotrophic lateral sclerosis (ALS), ocular diseases such as retinitis pigmentosa (RP), age-related macular degeneration (AMD), and glaucoma, and Huntington’s disease.

Ceregene’s gene therapy vectors deliver naturally occurring neurotrophic factors that slow or halt the neurodegeneration that underlies neurological disorders. Ceregene designs its therapies to slow, halt or possibly reverse neuronal degeneration, as opposed to currently accepted methods that merely try to compensate for loss of function. Using Ceregene’s technology, only a single treatment will be necessary to provide long-term therapy to degenerating nerve cells.